Renal Transplantation in Systemic Lupus Erythematosus: Outcome and Prognostic Factors in 50 Cases from a Single Centre
Table 2
Comparison of demographic features, clinical characteristics and treatment between SLE patients with graft failure and functioning graft.
Graft failure ()
Functioning graft ()
Gender female (%)
14 (93%)
27 (77%)
0.169
Age at diagnosis SLE (years)
22.4 ± 10
22.8 ± 11
0.758
Age at renal Tx (years)
41.3 ± 10.2
38.7 ± 12.0
0.280
Time SLE-nephritis (months)
17 ± 42.6
34.9 ± 75
0.412
Time nephritis dialysis (months)
39 ± 45.5
88.7 ± 80.6
0.038
Time on dialysis (months)
73.9 ± 60.6
35.7 ± 35.4
0.011
Time nephritis-Tx (months)
114.6 ± 64.2
120 ± 73.3
0.880
Dialysis before renal Tx (%):
HD
14 (93.3%)
19 (76.0%)
0.168
CAPD
2 (13.3%)
7 (28.0%)
0.251
HD and CAPD
1 (6.7%)
3 (12.0%)
0.516
Tx date (years)
1998 ± 7
2004 ± 6
0.036
Donor source (%):
Cadaveric
13 (86.7%)
16 (45.7%)
0.007
Living donor
2 (13.3%)
19 (54.3%)
—
Immunosuppressive regimen at Tx (grafts) (%):
Cyclosporine A
10 (66.6%)
9 (25.7%)
0.006
Mycophenolic acid
8 (53%)
31 (88.6%)
0.003
Tacrolimus
4 (27%)
23 (66%)
0.012
Positive anti-HCV antibodies (patients) (%)
12 (80%)
10 (28.6%)
0.001
Positive aPL antibodies (%)
1 (6.7%)
11 (31.4%)
0.058
Quantitative variables are presented as mean ± standard deviation and qualitative variables as number (percentage).
SLE: systemic lupus erythematosus; Tx: transplantation; HD: hemodialysis; CAPD: continuous ambulatory peritoneal dialysis; HCV: hepatitis C virus; aPL: anti-phospholipid antibodies.
